Tag: ANDA
Feb 2, 2026
Paragraph IV Certifications: How Generic Drug Makers Legally Challenge Patents
2 Comments
Paragraph IV certifications let generic drug makers legally challenge brand-name patents before launch. This Hatch-Waxman Act tool has saved over $1.7 trillion in healthcare costs and drives competition in the U.S. drug market.
Read More